表观遗传修饰如DNA甲基化(DNA methylation)和组蛋白去乙酰化(Histone Deacetylation)等对基因转录调控有重要作用,肿瘤细胞中常发生表观遗传修饰的异常,造成基因表达、细胞增殖的失调。
基于36个网页-相关网页
组蛋白去乙酰化酶 HDAC ; histone deacetylase ; histone deacetylases HDACs ; hi stone deacetyltransferases
和组蛋白去乙酰化酶 Histone Deacetyltranferase ; histone deacetylase
类组蛋白去乙酰化酶 Histone Deacetylases ; HDACIII ; histonedeacetylasesIII
包括组蛋白去乙酰化酶 Histone deacetylases ; HDACS
型组蛋白去乙酰化酶 histone deacetylases
的组蛋白去乙酰化酶 Histone deacetylases
与组蛋白去乙酰化酶 histone deacetylases
募集组蛋白去乙酰化酶 HDAC ; histone deacetyltransferases
组织蛋白去乙酰化酶 HD
认识到开发新颖治疗剂的要求，本发明提供新颖组蛋白去乙酰化酶抑制剂。
In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors.
靶向DNA甲基化和组蛋白去乙酰化酶的几个表观药物已经在临床试验中被测试。
Several epigenetic drugs targeting DNA methylation and histone deacetylation enzymes have been tested in clinical trials.
目的研究组蛋白去乙酰化酶抑制剂MS275对人多发性骨髓瘤细胞U266增殖的影响。
ObjectiveTo investigate the antitumor effect of MS275, a histone deacetylase inhibitor, on growth of the human myeloma cell line U266.
应用推荐